Aclaris Therapeutics Expands Leadership Team
June 27 2022 - 7:00AM
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage
biopharmaceutical company focused on developing novel drug
candidates for immuno-inflammatory diseases, today announced the
appointment of Gail Cawkwell, MD, PhD, as Chief Medical Officer,
effective today.
“We are excited to welcome Dr. Cawkwell to Aclaris at this time
as we are executing on a number of clinical programs,” said Dr.
Neal Walker, President and CEO of Aclaris. “Her leadership
experience in pharmaceutical development as well as her clinical
background will be extremely valuable in navigating the strategic
direction of our drug development pipeline.”
Dr. Cawkwell is a pediatric rheumatologist and epidemiologist
who brings over 20 years of pharmaceutical development and medical
affairs experience in large and small companies, and across
multiple disease areas. Most recently, she served as Senior Vice
President, Medical Affairs, Safety & Pharmacovigilance at
Intercept Pharmaceuticals, Inc. Prior to that, Dr. Cawkwell worked
for Purdue Pharma L.P. most recently as Special Advisor to the
Board of Directors, and Pfizer Inc., most recently as Vice
President Medicine Team Lead for Pfizer’s tofacitinib franchise.
Dr. Cawkwell also previously served as a Clinical Instructor of
Pediatrics at Columbia Presbyterian Health Center.
“As a rheumatologist, I am thrilled to join Aclaris, a company
passionate about finding treatment options for patients with
immuno-inflammatory conditions,” said Dr. Cawkwell. “I look forward
to helping Aclaris advance its clinical pipeline and delivering on
its clinical development goals.”
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical
company developing a pipeline of novel drug candidates to address
the needs of patients with immuno-inflammatory diseases who lack
satisfactory treatment options. The company has a multi-stage
portfolio of drug candidates powered by a robust R&D engine
exploring protein kinase regulation. For additional information,
please visit www.aclaristx.com.
Cautionary Note Regarding Forward-Looking
Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
as that term is defined in the Private Securities Litigation Reform
Act of 1995. These statements may be identified by words such as
“believe,” “expect,” “intend,” “may,” “plan,” “potential,” “will,”
and similar expressions, and are based on Aclaris’ current beliefs
and expectations. These forward-looking statements include the
future contributions of Dr. Cawkwell. These statements involve
risks and uncertainties that could cause actual results to differ
materially from those reflected in such statements. Risks and
uncertainties that may cause actual results to differ materially
include uncertainties inherent in the conduct of clinical trials,
Aclaris’ reliance on third parties over which it may not always
have full control, Aclaris’ ability to enter into strategic
partnerships on commercially reasonable terms, the uncertainty
regarding the COVID-19 pandemic and other risks and uncertainties
that are described in the Risk Factors section of Aclaris’ Annual
Report on Form 10-K for the year ended December 31, 2021 and other
filings Aclaris makes with the U.S. Securities and Exchange
Commission from time to time. These documents are available under
the “SEC Filings” page of the “Investors” section of Aclaris’
website at www.aclaristx.com. Any forward-looking statements speak
only as of the date of this press release and are based on
information available to Aclaris as of the date of this release,
and Aclaris assumes no obligation to, and does not intend to,
update any forward-looking statements, whether as a result of new
information, future events or otherwise.
Aclaris Contact
investors@aclaristx.com
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Apr 2023 to Apr 2024